Disease Area Lead Statistician — Biostatistics Director
Enregistrez cette offre et organisez votre recherche
Créez un compte gratuit pour enregistrer des offres d'emploi, créer des alertes et revenir à cette liste depuis votre tableau de bord.
En continuant, vous acceptez nos Conditions d’utilisation & Politique de confidentialité.
Argenx is seeking a Disease Area Lead Statistician to steer strategic statistical direction across Early Development, Research & Discovery and Clinical Development. You will lead a biostatistics team, enable data-driven decision making, and collaborate with cross-functional drug development scientists.
Reporting to the Head of Biostatistics & Statistical Modelling, you will deliver analyses, manage external partners, support regulatory interactions, and foster innovation and scientific rigor
-
Senior Biostatistics Director – Disease Area Lead
Il y a 4 jours
Oost-Vlaanderen, Oost-Vlaanderen, Belgique argenx SE Temps plein 120 000 € - 180 000 € Contratargenx SE is seeking a Disease Area Lead Statistician to steer statistical strategy across Early Development, Research & Discovery and Clinical Development. You will lead a team of biostatisticians, shaping analyses, interpretation, and reporting for multiple assets and indications throughout the product lifecycle.You will collaborate with QS and other...
-
Biostatistical Director
Il y a 4 jours
Oost-Vlaanderen, Oost-Vlaanderen, Belgique argenx SE Temps plein 120 000 € - 180 000 € ContratJoin us as we transform immunology and deliver medicines that help autoimmune patients get their lives back. argenx is preparing for multi-dimensional expansion to reach more patients through a rich pipeline of differentiated assets, led by VYVGART, our first-in-class neonatal Fc receptor blocker approved for the treatment of gMG, and with the potential to...
-
Biostatistical Director
Il y a 4 jours
Oost-Vlaanderen, Oost-Vlaanderen, Belgique Argenx Temps plein 110 000 € - 160 000 € ContratJoin us as we transform immunology and deliver medicines that help autoimmune patients get their lives back. argenx is preparing for multi-dimensional expansion to reach more patients through a rich pipeline of differentiated assets, led by VYVGART, our first-in-class neonatal Fc receptor blocker approved for the treatment of gMG, and with the potential to...